相似文献
1
The possible role of adenosine in the coronary dilator action of some pyrimidopyrimidines and pteridines.
Br J Pharmacol. 1970 Jun;39(2):287-95. doi: 10.1111/j.1476-5381.1970.tb12892.x.
2
Potentiation of adenosine and the adenine nucleotides by dipyridamole.
Br J Pharmacol Chemother. 1966 Nov;28(2):218-27. doi: 10.1111/j.1476-5381.1966.tb01888.x.
3
The potentiation of the action of adenosine on the guinea-pig heart.
Biochem Pharmacol. 1973 Feb 1;22(3):341-8. doi: 10.1016/0006-2952(73)90415-2.
4
Potentiation of adenosine by dipyridamole.
Nature. 1967 Apr 22;214(5086):390-1. doi: 10.1038/214390a0.
5
Potentiation of the coronary vasodilator effect of norepinephrine by 2,6-bis (diethanolamino)-4,8-dipiperidino-pyrimido (5,4-d) pyrimidine (dipyridamole).
Tohoku J Exp Med. 1968 Oct;96(2):207-8. doi: 10.1620/tjem.96.207.
6
Enhancement of coronary vasodilating action of adenosine by dilazep and dipyridamole in the dog.
Jpn J Pharmacol. 1974 Jun;24(3):471-8. doi: 10.1254/jjp.24.471.
7
[On the mechanism of action of coronary dilators].
Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1969;263(1):144-55.
8
[Competitive inhibition of adenosine aminase as a possible cause of the coronary dilating effects of a pyrimidopyrimidine combination].
Naunyn Schmiedebergs Arch Pharmakol Exp Pathol. 1966;255(1):107-19.
9
Potentiation of norepinephrine and adenosine in the renal circulation by 2,6-bis (diethanolamino)-4,8-dipiperidino-pyrimido (5,4-d) pyrimidine (dipyridamole) treatment (preliminary report).
Tohoku J Exp Med. 1968 Oct;96(2):161-4. doi: 10.1620/tjem.96.161.
10
Enhancement of coronary vasodilator action of adenosine triphosphate by dipyridamole.
Circ Res. 1967 Apr;20(4):403-8. doi: 10.1161/01.res.20.4.403.
引用本文的文献
1
Synthesis of Densely Functionalized Pyrimidouracils by Nickel(II)-Catalyzed Isocyanide Insertion.
Org Lett. 2020 Feb 7;22(3):914-919. doi: 10.1021/acs.orglett.9b04387. Epub 2020 Jan 16.
2
A non-adrenergic inhibitory nervous pathway in guinea-pig trachea.
Br J Pharmacol. 1974 Oct;52(2):167-74. doi: 10.1111/j.1476-5381.1974.tb09697.x.
3
Treatment of haemodynamic and electrocardiographic side-effects resulting from imipramine toxicity in rats and dogs.
Naunyn Schmiedebergs Arch Pharmacol. 1985 Aug;330(2):155-61. doi: 10.1007/BF00499909.
4
How does dipyridamole elevate extracellular adenosine concentration? Predictions from a three-compartment model of adenosine formation and inactivation.
Biochem J. 1986 Aug 1;237(3):845-51. doi: 10.1042/bj2370845.
5
Adenosine and dipyridamole actions and interactions on isolated coronary artery strips of cattle.
Br J Pharmacol. 1975 Nov;55(3):439-45. doi: 10.1111/j.1476-5381.1975.tb06949.x.
本文引用的文献
1
The potentiation of the action of adenosine on the guinea pig heart by ouabain.
J Pharmacol Exp Ther. 1955 May;114(1):119-25.
2
[COMPETITIVE INHIBITION OF CATALYZED ADENOSINE DIFFUSION AS THE MECHANISM OF THE CORONARY DILATING EFFECT OF A PYRIMIDO-PYRIMIDINE DERIVATIVE].
Pflugers Arch Gesamte Physiol Menschen Tiere. 1964 Jul 1;280:141-57.
3
EXPERIMENTAL APPROACHES TO THE DEVELOPMENT OF ANTIANGINAL DRUGS.
Adv Pharmacol (1962). 1964;3:1-82. doi: 10.1016/s1054-3589(08)61110-2.
4
[The elimination of adenosine from the blood under the influence of 2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido-(5,4-d) pyrimidine and papaverine].
Arzneimittelforschung. 1962 Nov;12:1130-1.
5
Effects of Persantin (RA8), a new coronary vasodilator, on coronary blood flow and cardiac dynamics in the dog.
Circ Res. 1962 Jan;10:35-44. doi: 10.1161/01.res.10.1.35.
6
The effect on the isolated rabbit heart of vagal stimulation and its modification by cocaine, hexamethonium and ouabain.
J Physiol. 1956 Mar 28;131(3):678-89. doi: 10.1113/jphysiol.1956.sp005493.
7
Potentiation of adenosine and the adenine nucleotides by dipyridamole.
Br J Pharmacol Chemother. 1966 Nov;28(2):218-27. doi: 10.1111/j.1476-5381.1966.tb01888.x.
8
Effects of dipyridamole on contractions of the cat's nictitating membrane.
Eur J Pharmacol. 1968 May;3(2):131-8. doi: 10.1016/0014-2999(68)90064-2.
9
[Competitive inhibition of adenosine aminase as a possible cause of the coronary dilating effects of a pyrimidopyrimidine combination].
Naunyn Schmiedebergs Arch Pharmakol Exp Pathol. 1966;255(1):107-19.
Zotero 插件